Long-term investors can consider buying the stock now or on dips for a possible target of over Rs 600-650 in the next 12 months which translates into an upside of over 13-22 per cent from Rs 530 recorded on 5 August, suggested experts.
Amish Shah turns bullish on pharma, remains cautious on IT
Indian equities are poised for a constructive phase, with strategists anticipating earnings acceleration and a potential revival in foreign investor interest. While near-term earnings surprises
December 15, 2025